GREY:NEPTF - Post by User
Post by
Intuitx2on Nov 01, 2019 9:58pm
22 Views
Post# 30300218
In Summary, it could appear that Trump's pick for FDA
In Summary, it could appear that Trump's pick for FDAChairman, from the M.D. Anderson Cancer Center, that center's work related to cannabis and Dr. Hahn being a cancer specialist may bode well for a more forward thinking approach towards cannabis within the realm of medical applications, or what I refer to as hyper growth phase II, which is beyond consumer retail applications of CBD and THC for recreational and instead goes into the world of advanced research, R&D, developing products for a global population....I believe I made an analogy in the past to founding technology companies from the past referencing Intel and Microsoft as two examples that reshaped society. We can't forget about Cisco and their routers that power the internet. Companies like Google and Amazon were mere off spring to the founding technologies and I view cannabis for medical applications in the same arena as founding technologies.
Realistically, with the right customers and technology advancements, I can easily see NEPT's stock price on the same playing field as Amazon in 8 years with global expansion, patents and previous items mentioned.
Looking through those eyes, I wonder what Dr. Graham Wood at NEPT is doing? I don't think he's working on flavored gummy bears.